News

Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)

Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)

Ian Nisbet, PhD

Chief Operating Officer, Cartherics Pty Ltd

As published in pharmaphorum

Background

The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to Antibody-Drug Conjugates (ADCs), highlighting their potential in cancer therapy [1, 2]. This development serves as an opportunity for companies to reflect on the […]

Karen Loudon2024-04-26T12:20:09+10:00April 26th, 2024|

Cartherics enters into Collaborative Research Agreement with TiCARos

Cartherics enters into Collaborative Research Agreement with TiCARos

Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer […]

Karen Loudon2024-04-02T13:48:04+11:00April 2nd, 2024|

Cartherics executes Option Agreement with The Ohio State University

Cartherics executes Option Agreement with The Ohio State University

TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS

Melbourne, Australia, 20 March 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP) from The Ohio State University (Ohio […]

Karen Loudon2024-03-20T12:56:13+11:00March 20th, 2024|

Cartherics: Leading the Charge in Immunotherapy for Solid Tumours

Cartherics: Leading the Charge in Immunotherapy for Solid Tumours

At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company’s cutting-edge strategies in combating solid tumours through cell-based immunotherapy. From leveraging stem cells to navigating regulatory pathways and entering clinical trials, Cartherics is on a mission to redefine cancer treatment. This interview highlights the challenges, […]

Karen Loudon2024-03-19T13:38:02+11:00March 19th, 2024|

Teal Ribbon Day: Raising awareness for ovarian cancer

Teal Ribbon Day: Raising awareness for ovarian cancer

Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed at an advanced stage, where it is very difficult to treat.

To help raise awareness for ovarian cancer, Cartherics hosted a Teal Ribbon Day afternoon tea. Our Teal Tea provided a great opportunity to bring people […]

Karen Loudon2024-03-08T13:39:16+11:00February 28th, 2024|

Cartherics to present and exhibit at Emergence 2024

Cartherics to present and exhibit at Emergence 2024

Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.

The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28^th February. His presentation will discuss:

Cartherics’ breakthrough approach to treating solid tumours.
How CTH-401, […]

Karen Loudon2024-02-22T15:57:01+11:00February 22nd, 2024|

Cartherics’ CEO discusses the future of solid tumour therapy

Cartherics’ CEO discusses the future of solid tumour therapy

Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the future of solid tumour therapy. In the interview Alan, shares insights into Cartherics’ cutting-edge technology, including the use of gene-edited natural killer (NK) cells and the strategic approach to leveraging a robust IP portfolio for […]

Karen Loudon2024-02-15T15:18:52+11:00February 15th, 2024|

Ovarian cancer: Biotech company Cartherics to start human trials of new drug

Ovarian cancer: Biotech company Cartherics to start human trials of new drug

There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when survival outcomes are worse. Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product designed to seek out and destroy the cells that cause ovarian cancer, with clinical trials planned for early next […]

Karen Loudon2024-02-12T15:37:35+11:00February 12th, 2024|

Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy

Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy

Melbourne, Australia, 1 February 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has successfully completed a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for a Phase I/II clinical trial of its […]

Karen Loudon2024-02-01T15:38:56+11:00February 1st, 2024|

Cartherics to present at Australia Biologics Festival 2024

Cartherics to present at Australia Biologics Festival 2024

Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at Crown Promenade in Melbourne.

The Australia Biologics Festival aims to gather the innovators, pioneers and leaders in the biologics industry, including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics, to showcase the […]

Karen Loudon2024-03-19T08:53:29+11:00January 23rd, 2024|

About us

Sign up to our newsletter